-
1.发明申请公开(公告)号：US20160229847A1
公开(公告)日：2016-08-11
申请号：US15022313
申请日：2014-09-22
Applicant: PFIZER INC.
Inventor： Martin Youngjin Pettersson , Christopher William am Ende , Michael Eric Green , Douglas Scott Johnson , Gregory Wayne Kauffman , Christopher William O'Donnell , Nandini Chaturbhai Patel , Antonia Friederike Stepan , Cory Michael Stiff , Chakrapani Subramanyam , Tuan Phong Tran , Patrick Robert Verhoest
IPC: C07D471/04 , C07D498/04
CPC classification number: C07D471/04 , C07D498/04
Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula II as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 公开了化合物的化合物和药学上可接受的盐，其中所述化合物具有如说明书中定义的式II的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
公开(公告)号：US10316021B2
公开(公告)日：2019-06-11
申请号：US15820679
申请日：2017-11-22
Applicant: Pfizer Inc.
Inventor： Natasha Mariam Kablaoui , Michael Eric Green , Justin Ian Montgomery , Michael Aaron Brodney , Patrick Robert Verhoest , Gregory Wayne Kauffman , Danica Antonia Rankic , Scot Richard Mente , Bruce Nelsen Rogers , Kapildev Kashmirilal Arora , Matthew Francis Dunn
IPC: C07D403/04 , C07D231/20 , C07D413/04 , C07D417/04 , A61P25/00
Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (κ-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.
-
![SUBSTITUTED PYRIDO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES](/abs-image/US/2017/06/15/US20170166566A1/abs.jpg.150x150.jpg)
公开(公告)号：US20170166566A1
公开(公告)日：2017-06-15
申请号：US15441882
申请日：2017-02-24
Applicant: Pfizer Inc.
Inventor： Martin Youngjin Pettersson , Christopher William am Ende , John Michael Humphrey , Douglas Scott Johnson , Gregory Wayne Kauffman , Danica Antonia Rankic , Antonia Friederike Stepan , Patrick Robert Verhoest
IPC: C07D471/04
CPC classification number: C07D471/04
Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R1, R2a, R2b, R4a, R4b,R5a, R5b, R6, R7, y and z are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US20160222007A1
公开(公告)日：2016-08-04
申请号：US15012954
申请日：2016-02-02
Applicant: Pfizer Inc.
Inventor： Martin Youngjin Pettersson , Christopher William am Ende , Douglas Scott Johnson , Gregory Wayne Kauffman , Antonia Friederike Stepan , Patrick Robert Verhoest
IPC: C07D471/04
CPC classification number: C07D471/04 , A61K31/4985 , A61P25/28
Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, R10, R11, and y are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 公开了化合物的化合物和药学上可接受的盐，其中化合物具有式I的结构，其中X，R1，R2a，R2b，R4a，R4b，R5a，R5b，R6，R7，R10，R11和y定义如上 在规范中。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
![Novel Pyrido[1,2-a]Pryazines And Their Use In The Treatment of Neurodegenerative and Neurological Disorders](/abs-image/US/2015/03/12/US20150072990A1/abs.jpg.150x150.jpg)
5.发明申请Novel Pyrido[1,2-a]Pryazines And Their Use In The Treatment of Neurodegenerative and Neurological Disorders 审中-公开新型吡啶并[1,2-a] Pryazine及其用于治疗神经退行性和神经性疾病公开(公告)号：US20150072990A1
公开(公告)日：2015-03-12
申请号：US14543020
申请日：2014-11-17
Applicant: Pfizer Inc.
Inventor： Martin Youngjin Pettersson , Douglas Scott Johnson , Chakrapani Subramanyam , Christopher John O'Donnell , Christopher William am Ende , Michael Eric Green , Nandini Chaturbhai Patel , Cory Michael Stiff , Tuan Phong Tran , Gregory Wayne Kauffman , Antonia Friederike Stepan , Patrick Robert Verhoest
IPC: C07D471/04
CPC classification number: C07D471/04
Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 公开了化合物的化合物和药学上可接受的盐，其中化合物具有说明书中定义的式I的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
Patent Agency Ranking
公开(公告)号：US09765073B2
公开(公告)日：2017-09-19
申请号：US15382778
申请日：2016-12-19
Applicant: Pfizer Inc.
Inventor： Martin Youngjin Pettersson , Christopher William am Ende , Douglas Scott Johnson , Gregory Wayne Kauffman , Antonia Friederike Stepan , Patrick Robert Verhoest
IPC: C07D471/04 , A61K31/4985
CPC classification number: C07D471/04 , A61K31/4985
Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, R10, R11, and y are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
![Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders](/abs-image/US/2017/09/05/US09751877B2/abs.jpg.150x150.jpg)
7.发明授权公开(公告)号：US09751877B2
公开(公告)日：2017-09-05
申请号：US14877118
申请日：2015-10-07
Applicant: Pfizer Inc.
Inventor： Martin Youngjin Pettersson , Douglas Scott Johnson , Chakrapani Subramanyam , Christopher John O'Donnell , Christopher William am Ende , Michael Eric Green , Nandini Chaturbhai Patel , Cory Michael Stiff , Tuan Phong Tran , Gregory Wayne Kauffman , Antonia Friederike Stepan , Patrick Robert Verhoest
IPC: A61K31/4985 , C07D471/04
CPC classification number: C07D471/04
Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
![Novel Pyrido[1,2-a]Pryazines And Their Use in the Treatment of Neurodegenerative and Neurological Disorders](/abs-image/US/2016/01/28/US20160024088A1/abs.jpg.150x150.jpg)
8.发明申请Novel Pyrido[1,2-a]Pryazines And Their Use in the Treatment of Neurodegenerative and Neurological Disorders 审中-公开新型吡啶并[1,2-a] Pryazine及其用于治疗神经退行性和神经性疾病公开(公告)号：US20160024088A1
公开(公告)日：2016-01-28
申请号：US14877118
申请日：2015-10-07
Applicant: Pfizer Inc.
Inventor： Martin Youngjin Pettersson , Douglas Scott Johnson , Chakrapani Subramanyam , Christopher John O'Donnell , Christopher William am Ende , Michael Eric Green , Nandini Chaturbhai Patel , Cory Michael Stiff , Tuan Phong Tran , Gregory Wayne Kauffman , Antonia Friederike Stepan , Patrick Robert Verhoest
IPC: C07D471/04
CPC classification number: C07D471/04
Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 公开了化合物的化合物和药学上可接受的盐，其中化合物具有说明书中定义的式I的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
![NOVEL CHROMENE AND 1,1a,2,7b-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES](/abs-image/US/2015/10/01/US20150274721A1/abs.jpg.150x150.jpg)
9.发明申请NOVEL CHROMENE AND 1,1a,2,7b-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES 审中-公开新氯仿和1,1a，2,7b-四氢环戊二烯并[C]吡喃基吡咯烷酮公开(公告)号：US20150274721A1
公开(公告)日：2015-10-01
申请号：US14670746
申请日：2015-03-27
Applicant: Pfizer Inc.
Inventor： Martin Youngjin Pettersson , Christopher William am Ende , John Michael Humphrey , Douglas Scott Johnson , Gregory Wayne Kauffman , Danica Antonia Rankic , Antonia Friederike Stepan , Patrick Robert Verhoest
IPC: C07D471/04
CPC classification number: C07D471/04
Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, y and z are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 公开了化合物的化合物和药学上可接受的盐，其中化合物具有式I的结构，其中X，R1，R2a，R2b，R4a，R4b，R5a，R5b，R6，R7，y和z如本说明书中所定义 。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
公开(公告)号：US20180148432A1
公开(公告)日：2018-05-31
申请号：US15820679
申请日：2017-11-22
Applicant: Pfizer Inc.
Inventor： Natasha Mariam Kablaoui , Michael Eric Green , Justin Ian Montgomery , Michael Aaron Brodney , Patrick Robert Verhoest , Gregory Wayne Kauffman , Danica Antonia Rankic , Scot Richard Mente , Bruce Nelsen Rogers , Kapildev Kashmirilal Arora , Matthew Francis Dunn
IPC: C07D403/04 , C07D417/04 , A61P25/00 , C07D231/20 , C07D413/04
CPC classification number: C07D403/04 , A61P25/00 , C07B2200/13 , C07D231/20 , C07D413/04 , C07D417/04
Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (κ-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.023 seconds)
